India's Bharat Biotech Claims 'Robust Immune Response' in Animal Trial for COVID-19 Vaccine, an Industrial Info Market Brief
Attachment: Bharat Biotech 0920
Indian bio-pharma major Bharat Biotech International Limited (BBIL), which has partnered with the Indian Council of Medical Research's (ICMR) National Institute of Virology (NIV) to manufacture and distribute India's first indigenously developed COVID-19 vaccine, says its vaccine candidate Covaxin was found to generate robust immune responses in non-human primates.
